MedPath

Safety and Efficacy of Dose Conversion From Vicodin® to Buprenorphine Transdermal System (Butrans™) in Subjects With OA Pain

Phase 3
Completed
Conditions
Osteoarthritis
Interventions
Registration Number
NCT00312572
Lead Sponsor
Purdue Pharma LP
Brief Summary

The objective of this study is to evaluate the safety and efficacy of dose conversion from hydrocodone/ acetaminophen (Vicodin®) to the buprenorphine transdermal system (Butrans™) in subjects with osteoarthritis pain of the hip or knee. The double-blind treatment intervention duration is 2 weeks during which time supplemental analgesic medication will be allowed.

Detailed Description

Buprenorphine is a synthetic opioid analgesic with over 25 years of international clinical experience indicating it to be safe and effective in a variety of therapeutic situations for the relief of moderate to severe pain.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
204
Inclusion Criteria
  • osteoarthritis of the hip or knee taking a regularly scheduled regimen of hydrocodone/ acetaminophen for their osteoarthritis OA pain.
Exclusion Criteria
  • currently have condition requiring a stable regimen of acetaminophen (APAP).
  • a history of chronic conditions, other than OA of the hip or knee joints, requiring frequent, intermittent analgesic therapy.

Other protocol-specific exclusion/inclusion criteria may apply.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
BTDS 20Buprenorphine transdermal patchInitial doses (Level 1) of BTDS 20.
BTDS10/20Buprenorphine transdermal patchInitial doses (Level 1) of BTDS 10. Subjects were allowed to have their doses adjusted to BTDS 20 (Level 2) on or after day 4.
Primary Outcome Measures
NameTimeMethod
The Percentage of Subjects Who Completed the 14-day Double-blind Phase.14 days

The indicator variable was 1 = completion, and 0 = noncompletion. For the primary efficacy analysis, the percentage of subjects who completed the double-blind phase was computed with its 95% confidence interval (CI) for each treatment regimen (starting dose of BTDS 10 or BTDS 20) across and within baseline Vicodin® stratum (15 to 22.5mg/day vs \>22.5 to 30 mg/day as determined by the daily average hydrocodone dose during the run-in period).

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (36)

HealthCare Research LLC

🇺🇸

St. Louis, Missouri, United States

Lifespan Research Foundation, Inc.

🇺🇸

Miami, Florida, United States

Redpoint Research

🇺🇸

Phoenix, Arizona, United States

Southern Drug Research

🇺🇸

Birmingham, Alabama, United States

Advanced Clinical Therapeutics

🇺🇸

Tucson, Arizona, United States

Advanced Clinical Research Institute

🇺🇸

Anaheim, California, United States

Miami Beach Anesthesiology Associates

🇺🇸

Miami Beach, Florida, United States

Kaiser Permanente

🇺🇸

Escondido, California, United States

Univ. of Southern California

🇺🇸

Santa Monica, California, United States

Lovelace Scientific Resources

🇺🇸

Beverly Hills, California, United States

The Medford Medical Clinic

🇺🇸

Medford, Oregon, United States

Renaissance Clinical Research & Hypertension Clinic

🇺🇸

Dallas, Texas, United States

The Arthritis and Osteoporosis Center

🇺🇸

Orangeburg, South Carolina, United States

Spine Care Southwest.

🇺🇸

Houston, Texas, United States

Intermountain Orthopaedics

🇺🇸

Boise, Idaho, United States

West Broward Rheumatology Association, Inc.

🇺🇸

Tamarac, Florida, United States

Hot Springs Mercy Pain Clinic

🇺🇸

Hot Springs, Arkansas, United States

Arthritis Center of CT

🇺🇸

Waterbury, Connecticut, United States

Neuro Science and Spine Assoc.

🇺🇸

Naples, Florida, United States

Commonwealth Biomedical Research, LLC

🇺🇸

Madisonville, Kentucky, United States

Clinical Pharmacology Study Group

🇺🇸

Worcester, Massachusetts, United States

Northeast Pain Research Center

🇺🇸

Barrington, New Hampshire, United States

Dayton Primary and Urgent Care

🇺🇸

Dayton, Ohio, United States

KRK Medical Research

🇺🇸

Richardson, Texas, United States

Tucson Orthopedic Institute

🇺🇸

Tucson, Arizona, United States

Private Practice

🇺🇸

Pine Bluff, Arkansas, United States

Monroe Medical Foundation

🇺🇸

Monroe, Wisconsin, United States

Southbay Pharma Research

🇺🇸

Buena Park, California, United States

PCM Medical Services

🇺🇸

Lansing, Michigan, United States

Community Medical Providers

🇺🇸

Clovis, California, United States

Westside Family Medical Center

🇺🇸

Kalamazoo, Michigan, United States

The Arthritis Clinic and Carolina Bone and Joint

🇺🇸

Charlotte, North Carolina, United States

Bluegrass Orthopaedics

🇺🇸

Lexington, Kentucky, United States

Dolby Providers, Inc.

🇺🇸

New Orleans, Louisiana, United States

CEDRA Clinical Research,

🇺🇸

Austin, Texas, United States

University of Kansas Medical Center

🇺🇸

Kansas City, Kansas, United States

© Copyright 2025. All Rights Reserved by MedPath